Athersys, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Athersys, Inc. - overview
Established
1995
Location
Cleveland, OH, US
Primary Industry
Biotechnology
About
Based in Ohio, US, and founded in 1995 by Gil Van Bokkelen and John Harrington, Athersys, Inc. operates as a clinical-stage biotechnology company that is focused on the field of regenerative medicine. The company received investments from Accipiter Capital Management, MPM Capital, OrbiMed Advisors, Pappas Capital, RA Capital, Radius Ventures, and Tekla Capital Management in June 2007, National Institute of Neurological Disorders and Stroke in February 2012, Pappas Capital in February 2014, and Aspire Capital in February 2018, and in July 2021, the firm entered into a purchase agreement with Aspire Capital. As of 2021, the company is trading on the NASDAQ Capital Market under the symbol “ATHX” and William Lehmann is the Interim CEO of the company.
The firm develops novel and proprietary therapies designed to enhance and extend the quality of human life and to treat significant and life-threatening diseases. The firm offers MultiStem, which is a patented stem cell therapy platform for disease indications in areas of neurological, cardiovascular, immune, and inflammatory disease areas, as well as other critical care indications where there is a substantial unmet medical need. As of 2021, the company's MultiStem pipeline programs consist of Phase 3 clinical trial in North America and Europe, and a registrational trial in Japan in partnership with HEALIOS K. K.
to treat ischemic stroke. The company generated a revenue of USD 5. 6 million with a net loss of USD 44. 6 million in 2019, and USD 24.
3 million with a net loss of 24. 3 million in 2018.
Current Investors
National Institute of Neurological Disorders and Stroke, OrbiMed Advisors, Pappas Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.athersys.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Athersys, Inc. - timeline of key events
Athersys, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bankruptcy/Write-off | Completed | Athersys, Inc. | - |
Displaying 1 - 1 of 1
Athersys, Inc. - employee data
Athersys, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Founder and Board Member | BM | ||||||
| Chairman - Board of Governors | BM | ||||||
| Member of the Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.